A device developed by MGH investigators may bring rapid, accurate molecular diagnosis of tumors and other diseases to locations lacking the latest medical technology
A device developed by Massachusetts General Hospital investigators may bring rapid, accurate molecular diagnosis of tumors and other diseases to locations lacking the latest medical technology. In their report appearing in PNAS Early Edition, the researchers describe a smartphone-based device that uses the kind of technology used to make holograms to collect detailed microscopic images for digital analysis of the molecular composition of cells and tissues.
“The global burden of cancer, limited access to prompt pathology services in many regions and emerging cell profiling technologies increase the need for low-cost, portable and rapid diagnostic approaches that can be delivered at the point of care,” says Cesar Castro, MD, of the MGH Cancer Center and Center for Systems Biology, co-lead author of the report. “The emerging genomic and biological data for various cancers, which can be essential to choosing the most appropriate therapy, supports the need for molecular profiling strategies that are more accessible to providers, clinical investigators and patients; and we believe the platform we have developed provides essential features at an extraordinary low cost.”
The device the team has developed – called the D3 (digital diffraction diagnosis) system – features an imaging module with a battery-powered LED light clipped onto a standard smartphone that records high-resolution imaging data with its camera. With a much greater field of view than traditional microscopy, the D3 system is capable of recording data on more than 100,000 cells from a blood or tissue sample in a single image. The data can then be transmitted for analysis to a remote graphic-processing server via a secure, encrypted cloud service, and the results rapidly returned to the point of care.
For molecular analysis of tumors, a sample of blood or tissue is labeled with microbeads that bind to known cancer-related molecules and loaded into the D3 imaging module. After the image is recorded and data transmitted to the server, the presence of specific molecules is detected by analyzing the diffraction patterns generated by the microbeads. The use of variously sized or coated beads may offer unique diffraction signatures to facilitate detection. A numerical algorithm developed by the research team for the D3 platform is capable of distinguishing cells from beads and of analyzing as much as 10 MB of data in less than nine hundredths of a second.
A pilot test of the system with cancer cell lines detected the presence of tumor proteins with an accuracy matching that of the current gold standard for molecular profiling, and the larger field of view enabled simultaneous analysis of more than 100,000 cells at a time. The investigators then conducted analysis of cervical biopsy samples from 25 women with abnormal PAP smears – samples collected along with those used for clinical diagnosis – using microbeads tagged with antibodies against three published markers of cervical cancer. Based on the number of antibody-tagged microbeads binding to cells, D3 analysis promptly and reliably categorized biopsy samples as high-risk, low-risk or benign, with results matching those of conventional pathologic analysis.
Read more: Smartphone-based device could provide rapid, low-cost molecular tumor diagnosis
The Latest on: Molecular tumor diagnosis
[google_news title=”” keyword=”Molecular tumor diagnosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Molecular tumor diagnosis
- New DNA nanomachine targets breast cancer with precisionon March 28, 2024 at 7:46 pm
Breast cancer is the most common malignancy in women, posing a serious threat to the female health. Due to the high inter- and intra-tumoral heterogeneity of breast cancer, clinical treatment and ...
- USA Health researchers identify potential biomarker for early pancreatic cancer diagnosison March 27, 2024 at 3:33 pm
Cancer researchers with the USA Health Mitchell Cancer Institute and the University of South Alabama have identified a potential biomarker for early diagnosis and prognosis of pancreatic cancer.
- Global Multiplex Molecular Diagnostics Market is anticipated to reach US$ 39.25 Billion by 2032on March 25, 2024 at 7:16 pm
Global Multiplex Molecular Diagnostics Market is anticipated to surge to an astounding US$ 39.25 Billion by 2032.
- Molecular Profiling and Companion Diagnostics: Where is Personalized Medicine in Cancer Heading?on March 21, 2024 at 5:00 pm
[9] Personalized medicine becomes more significant when we realize that the individual tumor possesses its own unique characteristics in terms of molecular make up, tumor microenvironment and its ...
- As Molecular Profiling Takes Center Stage, There Is Hope For Targeted Treatments For Cancer Patientson March 20, 2024 at 7:32 am
Amy Cripps, MD, a distinguished medical oncologist, stands as a testament to the transformative impact of molecular medicine in her practice.
- Possible Treatment Identified for Rare Kidney Cancer Subtypeon March 19, 2024 at 5:00 pm
“Since they are different tumors, I think the treatment should be different. And also, the diagnosis … sometimes it is difficult. Sometimes we need immunohistochemistry and molecular testing to ...
- Subtyping of breast cancer cell lines reveals insights into cancer-relevant geneson March 19, 2024 at 9:26 am
However, breast cancer is not a uniform disease, as there are many different types. These subtypes exhibit different molecular alterations, for example in relation to the activity of hormone receptors ...
- Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Optionson March 18, 2024 at 5:53 am
Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.
- What Is Luminal B Breast Cancer? Olivia Munn’s Diagnosis Explained.on March 13, 2024 at 1:38 pm
Actress Olivia Munn announced on Instagram that she was diagnosed with breast cancer in 2023. Specifically, Munn was diagnosed with luminal B breast cancer, which is one of the molecular subtypes of ...
- Europe Colorectal Cancer Screening and Diagnostic Market Report: A $7.30 Billion Market by 2033, Growing at a CAGR of 5.72% During 2023-2033on March 7, 2024 at 4:00 pm
advancements in genomics and molecular diagnostics, and a rising need for colorectal cancer examination. The Europe colorectal cancer screening and diagnostic market are experiencing significant ...
via Bing News